NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...
NICE has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...
A major trial finds the beta blocker bisoprolol neither improves nor worsens outcomes in people with COPD, despite the cardiovascular risk.
Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results